12 results about "Calreticulin" patented technology

Provided are nanobodies that bind human calreticulin, fusion proteins including the nanobodies, pharmaceutical compositions including the nanobodies or fusion proteins, and radioconjugates of the nanobodies or fusion proteins.

A diagnostic, preventive, or therapeutic agent may be used for a myeloproliferative neoplasm. An antibody or a functional fragment thereof that binds to a cleaved mutant CALR protein, may include an antigen-recognition site in (a) a polypeptide chain having an amino acid sequence set forth in SEQ ID NO: 1 or (b) a polypeptide chain having an amino acid sequence having deletion, substitution, or addition of one to several amino acids in SEQ ID NO: 1; and a diagnostic, preventive, or therapeutic agent for a myeloproliferative neoplasm containing the antibody.

The present disclosure provides polymeric matrices comprising calreticulin (CRbT) and methods of producing and using such matrices. The polymeric matrices are useful in treatment of wounds (e.g., chronic diabetic wound).

Provided are a corn peptide having an anti-tumor effect, and a preparation method therefor and a use thereof. The corn peptide can obviously eliminate reactive oxygen species in tumor cells, increase the concentration of free calcium ions in the cytoplasm of the tumor cells and reduce the mitochondrial membrane potential of the tumor cells, and also can enhance the expression levels of mRNA and proteins of an IP3R and calreticulin, and further affect the calcium homeostasis of the tumor cells. In addition, the corn peptide can up-regulate the expression of tumor suppressor genes PTEN, P21 and P27, down-regulate the expression of a cell proliferation marker PCNA and a tumor-promoting gene Akt, and mediate an anti-tumor effect by means of PTEN and Akt cell signaling pathways.

The invention discloses a tumor cell vaccine, a preparation method thereof and application of the tumor cell vaccine in preparation of diffuse large B-cell lymphoma immunotherapy drugs. Research finds that after a cell culture medium is subjected to arginine deprivation treatment, DLBCL cell proliferation is remarkably inhibited, ICD (immunogenic cell death) is induced, and ICD key markers including calreticulin (CALR) membrane ectropion, high mobility group protein B1 (HMGB1) and ATP are released. These molecules activate dendritic cells and CD8 + T cells, enhancing antigen presentation and immune response. Further zoology experiment results show that the whole-cell vaccine subjected to arginine deprivation treatment shows a good anti-tumor effect in a mouse model.

The problem addressed by the present invention is to produce a novel antibody recognizing a mutant CALR protein at a site distinct from the sites recognized by conventional antibodies, and to provide pharmaceuticals using the same. The present invention provides a composition for treating a tumor, the composition comprising an antibody or an antigen-binding fragment thereof that binds to a region N-terminal to a mutation site in a mutant calreticulin and binds to the mutant calreticulin present on the cell surface. The present invention also provides a method for producing an antibody that binds to a region N-terminal to a mutation site in a mutant calreticulin, said method comprising a step for screening: an antibody that binds to the mutant calreticulin present on a cell surface; or an antibody that binds to a dimer of the mutant calreticulin.

The present disclosure relates to binding domains that bind Calreticulin (CALR) and binding domain that binds to CD3, as well as binding moieties comprising such binding domains. The present disclosure further relates to the use of such binding domains or binding moieties in the treatment of cancer. The present disclosure also relates to nucleic acid encoding such binding domains or binding moieties, and a vector and cell comprising such nucleic acid.

The present disclosure relates to antibodies, and antigen-binding fragments thereof, that bind to mutant calreticulin. The present disclosure also relates to bispecific antibodies, and bispecific antigen-binding fragments thereof, that bind to mutant calreticulin and cluster of differentiation 3. Also provided are cells expressing the antibodies, polynucleotides and vectors expressing all of some of the antibodies, pharmaceutical compositions comprising the antibodies, and methods of inhibiting the growth or proliferation, or treating, myeloproliferative neoplasm.

The present disclosure relates to antibodies and antigen-binding fragments thereof that bind to a mutant calreticulin. The disclosure also relates to bispecific antibodies and bispecific antigen-binding fragments thereof that bind to mutant calreticulin and cluster of differentiation 3. Also provided are cells expressing the antibodies, polynucleotides and vectors expressing all of some of the antibodies, pharmaceutical compositions comprising the antibodies, and methods of inhibiting the growth or proliferation of or treating myeloproliferative tumors.

The present application provides methods for the treatment of clonal hematopoietic disorders using compounds that modulate kinase activity or antibodies that binds to human mutant calreticulin (CALR).

The present invention relates to calsequestrin-based metal ion reactive particles and their applications. More specifically, the invention concerns calsequestrin-based metal ion reactive particles, which are prepared by combining bioactive substances frequently used in pharmaceuticals and cosmetics with calsequestrin (CSQ) and then reacting them with metal ions. This invention also relates to the use of these particles as drug delivery carriers, pharmaceutical compositions, or vaccines. The metal ion reactive particles according to the present invention can enhance the in vivo and in vitro stability of bioactive substances, prolong their active duration, increase their half-life in the body, and improve antigen delivery efficiency.